We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?
- Authors
Tatham, Kate C.; Shankar-Hari, Manu; Arabi, Yaseen M.
- Abstract
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The trial population of REMDACTA trial appears similar to the RECOVERY Trial that showed benefit with tocilizumab, with one key difference: RECOVERY trial eligibility criteria included C-reactive protein (CRP) values > 75 mg/L as a marker of inflammation [[7]]. However, in the RECOVERY Trial that enrolled a similar target population, there was additional benefit with tocilizumab in those patients who got corticosteroids [[7]], a treatment effect that was replicated in critically ill patients [[15]] and in all illness severity states within the PMA [[5]].
- Subjects
INTERLEUKIN receptors; COVID-19; MEDICAL research; MEDICAL personnel
- Publication
Intensive Care Medicine, 2021, Vol 47, Issue 11, p1315
- ISSN
0342-4642
- Publication type
Editorial
- DOI
10.1007/s00134-021-06540-w